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Osteoporosis in hemodialysis patients is associated with high
morbidity and mortality and, although extensively studied by
noninvasive methods, has never been assessed through bone
biopsy. The aim of this study was to use histomorphometry
to evaluate osteoporosis and identify factors related to its
development in hemodialysis patients. We conducted a
cross-sectional study involving 98 patients (35 women and
63 men; mean age: 48.4713 years) on hemodialysis for
36.9724.7 months. Patients were submitted to transiliac
bone biopsy with double tetracycline labeling. The bone
metabolism factors ionized calcium, phosphorus, bone
alkaline phosphatase, deoxypyridinoline, intact parathyroid
hormone, and 25(OH) vitamin D were evaluated, as were the
bone remodeling cytokines osteoprotegerin (OPG), soluble
receptor-activator of NF-jb ligand (sRANKL) and tumor
necrosis factor-a (TNF)a. Osteoporosis was defined as
trabecular bone volume (BV/TV) greater than 1 s.d. below
normal (men o17.4%; women o14.7%). Forty-five patients
(46%) presented osteoporosis, which was correlated with
white race. We found BV/TV to correlate with age, OPG/
sRANKL ratio, TNFa levels, and length of amenorrhea. In
multiple regression analysis adjusted for sex and age, length
of amenorrhea, white race, and OPG/sRANKL ratio were
independent determinants of BV/TV. Histomorphometric
analysis demonstrated that osteoporotic patients presented
normal eroded surface and low bone formation rate (BFR/BS).
Osteoporosis is prevalent in hemodialysis patients. Low BFR/
BS could be involved in its development, even when bone
resorption is normal. Cytokines may also play a role as may
traditional risk factors such as advanced age, hypogonadism,
and white race.
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Osteoporosis is a common bone disorder among the elderly.
It occurs owing to disruption of the bone remodeling cycle,
which leads to bone loss. In addition to its known association
with fractures,1 osteoporosis has recently been associated
with vascular disease.2 As uremia induces a derangement in
bone and mineral homeostasis known as renal osteodystro-
phy (ROD), it is logical to assume that patients with chronic
kidney disease (CKD) are at risk for developing osteoporosis
and its comorbidities. In fact, such patients are more prone
to fractures than are individuals in the general population,3–5
and it has also been suggested that there is a relationship
between ROD and vascular calcification.6,7 The increasing
surveillance of hemodialysis patients, together with the
growing numbers of older individuals entering into this type
of treatment, increases the importance of studying bone loss
in hemodialysis patients.
The diagnosis of osteopenia/osteoporosis, as proposed by
the World Health Organization (WHO),1 is based on bone
mineral density, measured by dual-energy X-ray absorptio-
metry. However, this method has proven to be reliable only in
white women, and its accuracy in evaluating men, children,
and individuals belonging to other ethnic groups remains
uncertain, as does its applicability to all types of secondary
osteoporosis, including ROD. Therefore, caution should be
taken when extrapolating this diagnostic approach to these
other situations.8
It has been suggested that bone biopsy, the gold standard
method for the diagnosis of ROD, could be applied to
characterize osteopenia/osteoporosis in CKD patients.9 Bone
biopsy followed by histomorphometric analysis is the first
quantitative method that can be used to elucidate how bone
remodeling abnormalities can cause bone loss.10 This
technique also provides qualitative information regarding
microarchitectural changes in bone tissue. However, this
approach has been underused in the evaluation of osteo-
porosis in CKD patients.
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The aim of this study was to employ bone biopsy followed
by histomorphometric analysis in order to assess the preva-
lence of osteoporosis in a population of patients on hemo-
dialysis, as well as to identify factors that might contribute to
its development.
RESULTS
According to our diagnostic criteria, patients were divided
into osteoporotic (OP) and non-osteoporotic (NOP) groups
that encompassed, respectively, 45 (46%) and 53 (54%) of the
patients. Clinical and biochemical characteristics of both
groups are shown in Table 1. There were no differences
between the two groups regarding age, etiology of CKD, time
on hemodialysis, or body mass index. Regarding gender, we
observed a higher frequency of men in OP group, although
statistically nonsignificant (P¼ 0.08). There was a strong
correlation between osteoporosis and being of the white race
(odds ratio¼ 3.58; 95% confidence interval¼ 1.40–9.27;
P¼ 0.005), whereas calcitriol therapy tended to be a protec-
tive factor against osteoporosis (odds ratio¼ 0.40; 95%
confidence interval¼ 0.15–1.05; P¼ 0.06). Osteoporosis
was also associated with duration of amenorrhea longer than
48 months (odds ratio¼ 10; 95% confidence interval¼
1.02–127.99; P¼ 0.02). We found that osteoporosis did not
correlate with diabetes mellitus, previous corticotherapy, or
smoking. No differences regarding biochemical parameters
were noted, except for a significantly higher osteoprotegerin
(OPG)/soluble receptor-activator of NF-kb ligand (sRANKL)
ratio and significantly lower tumor necrosis factor-a (TNFa)
levels in the OP group. Interestingly, mean levels of intact
parathyroid hormone (iPTH) in both groups were near the
target range for hemodialysis patients.9
Table 2 shows the result of the bone histomorphometry.
Regarding static parameters, trabecular separation was
significantly higher in the OP group than in the NOP group,
whereas trabecular thickness, trabecular number, and trabe-
cular bone volume (BV/TV), the last being the parameter
used to diagnose osteoporosis, were significantly lower. No
statistically significant difference was observed between the
other static parameters. Analysis of the dynamic parameters
indicated that bone formation rate (BFR/BS) was signifi-
cantly lower and mineralization lag time was significantly
higher in the OP group than in the NOP group.
Based on histomorphometry, adynamic bone disease
(n¼ 55; 56.1%) was the most common type of ROD,
followed by mixed uremic osteodystrophy (n¼ 21; 21.4%),
predominant hyperparathyroid bone disease (n¼ 12; 12.2%),
and osteomalacia (n¼ 1; 1.1%). Aluminum-related bone
disease was detected in 24.5% of the patients. Normal bone
Table 1 | Clinical and biochemical characteristics of OP and
NOP patients
Variable OP (n=45) NOP (n=53)
Age (years) 51714.1 46.3711.7
Gender
Male 33 (73%) 30 (57%)
Female 12 (27%) 23 (43%)
Race
White 33 (73%)w 23 (43%)
Non-white 12 (27%) 30 (57%)
Etiology of CKD
Unknown 12 (27%) 15 (33%)
Hypertension 14 (31%) 13 (25%)
CGN 4 (9%) 13 (25%)
DM 3 (6%) 6 (11%)
Other 12 (27%) 6 (11%)
Time on HD (months) 33.9723.8 39.5725.5
BMI (kg/m2) 24.173.8 25.474.6
History of DM 6 (13%) 10 (22%)
Calcitriol therapy 14 (41%) 33 (62%)
Corticotherapy 11 (24%) 12 (22%)
Smoking 11 (24%) 14 (26%)
Amenorrhea 448 months 5/12 (41.6%)w 2/23 (8.7%)
Ionized calcium (mmol/l) 1.2370.08 1.2470.09
Phosphorus (mg/dl) 7.071.2 7.372.1
BAP (U/l)* 22.5711.7 35.6740.9
Deoxypyridinoline (nmol/l)* 76.1766.4 142.27192.0
iPTH (pg/ml) 296.47245.7 388.37354.5
25(OH) vitamin D (ng/dl)* 34.8717.2 31.0712.0
OPG (pg/ml)* 187.7765.4 164.4776.0
sRANKL (pg/ml)* 4.677.7 6.279.5
OPG/sRANKL ratio* 96.4758.3w 74.2763.6
TNFa (pg/Ml)* 3.774.0w 6.078.0
Estradiol (ng/dl)** 3.071.3 6.576.6
Free testosterone (pg/ml)*** 369.67153.5 384.87208.0
BAP, bone alkaline phosphatase; BMI, body mass index; CGN, chronic glomerulone-
phritis; CKD, chronic kidney disease; DM, diabetes mellitus; HD, hemodialysis; iPTH,
intact parathyroid hormone; NOP, non-osteoporotic; OP, osteoporotic; OPG,
osteoprotegerin; sRANKL, soluble receptor-activator of NF-kB ligand; TNFa, tumor
necrosis factor-a.
Values shown as n (%) or as mean7s.d.
*n=86; **n=28; ***n=50.
wPo 0.05.
Table 2 | Comparison of histomorphometric parameters
between OP and NOP patients
Variable OP (n=45) NOP (n=53) Reference range
BV/TV (%) 12.272.6* 22.375.1 25.578.1(M);
22.077.3(F)
OV/BV (%) 3.273.2 4.074.0 3.273.0
Ob.S/BS (%) 4.475.7 6.777.9 2.1373.8
ES/BS (%) 4.273.2 6.976.1 3.1574.81
Oc.S/BS (%) 0.7170.69 1.171.1 0.0770.22
Tb.Th (mm) 103.4715.7ww 122.1718.4 126.5731.4
Tb.Sp (mm) 781.27231.15ww 439.7793.1 402.77156.8
Tb.N/mm 1.3270.95ww 1.870.37 2.0570.72
Fb.V/TV (%) 0.1170.26 0.5271.78 0
Al.S/BS (%) 30.6732.9 18.9723.3 0
BFR/BS (m3/m2/day) 0.0270.04w 0.0570.07 0.1370.07
Mlt (days) 95.57104.7w 55.6755.7 21.372.3
Al.S/BS, aluminum bone surface; BFR/BS, bone formation rate; BV/TV, trabecular
bone volume; ES/BS, eroded surface; Fb.V/TV, fibrosis volume; Mlt, mineralization
lag-time; Ob.S/BS, osteoblast surface; Oc.S/BS, osteoclast surface; OV/BV, osteoid
volume; Tb.Sp, trabecular separation; Tb.N, trabecular number; Tb.Th, trabecular
thickness.
Normal or more than 1 s.d. above the normal range, mineralization lag time more
than 1 s.d. above the normal range.
Values expressed as mean7s.d.
wPo0.05; wwPo0.000001.
*Not applicable.
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histology was identified in four (4.1%) and isolated
osteoporosis in three (3.1%) patients. Although osteoporosis
was present in all forms of ROD (Figure 1), no association
was found between osteoporosis and any type of ROD.
As shown in Table 3, BV/TV correlated positively with
TNFa levels and negatively with age, length of amenorrhea,
and OPG/sRANKL ratio. A borderline correlation was
observed between BV/TV and body mass index. We found
that BV/TV was not correlated with estradiol, free testoster-
one, iPTH, or 25(OH) vitamin D levels. All variables reaching
the level of statistical significance in the univariate analysis
were included in the regression model. Multiple stepwise
regression analysis adjusted for sex and age (Table 4) revealed
that being of the white race, length of amenorrhea and OPG/
sRANKL ratio were independent determinants of BV/TV.
Other histomorphometric parameters also correlated with
cytokine levels. We found a negative correlation between
BFR/BS and OPG/sRANKL ratio (P¼ 0.05) and a positive
correlation between BFR/BS and TNFa levels (P¼ 0.01).
Eroded surface correlated weakly with OPG/sRANKL ratio
(P¼ 0.06), but not at all with TNFa levels. Neither osteoclast
surface nor osteoblast surface correlated with cytokine levels.
DISCUSSION
In this bone histomorphometry-based study, we detected a
high prevalence (46%) of osteoporosis in a relatively young
population of hemodialysis patients. In addition, low BV/TV
was observed in patients as young as 22 years old. These
findings indicate that bone loss likely begins much earlier in
hemodialysis patients than in the general population, in
which such bone loss is not typically in patients less than 40
years of age.11
Many bone disorders, such as osteoporosis and ROD,
develop as a result of an imbalance between bone formation
and bone resorption. Bone biopsy followed by histomorpho-
metric analysis is still the gold standard for evaluating such
disorders.12,13 In our study, osteoporosis was characterized by
normal eroded surface and slightly increased osteoclast
surface (both bone resorption parameters), followed by low
BFR/BS. Bone microarchitecture was highly altered, as
demonstrated by reduced trabecular thickness and trabecular
number, as well as by increased trabecular separation. These
changes would lead to both increased bone fragility and
increased fracture risk.14 In contrast to these bone biopsy
results, the determination of serum levels of iPTH, as well as
of serum markers of bone formation (bone alkaline
phosphatase) and resorption (deoxypyridinoline), showed
no difference between OP and NOP patients.
Another interesting finding of this study was the
distribution of osteoporosis among the different forms of
ROD. Osteoporosis was present in both low bone turnover
states (adynamic bone disease and osteomalacia) and high
bone turnover states (predominant hyperparathyroid bone
disease and mixed uremic osteodystrophy). The well-known
hallmark of ROD is an uncoupled bone remodeling cycle,
which can lead to bone loss if bone resorption becomes
proportionally greater than bone formation. Therefore, the
high occurrence of osteoporosis (49%) in patients with
adynamic bone disease could be owing to the low bone
formation in the presence of normal to slightly increased
bone resorption. The coexistence of bone loss with adynamic
bone disease could, in part, explain its association with a high
rate of fractures.3,5 In predominant hyperparathyroid bone
disease patients, the low prevalence of osteoporosis (Figure 1)
could be related to the way PTH affects bone. Excess PTH
generally has catabolic effects on cortical bone and anabolic
effects on trabecular bone,15–18 the latter being the type of
tissue that was the focus of this study. Therefore, secondary
hyperparathyroidism would be to some degree protective
against trabecular bone loss. In contrast, as an iPTH level
41000 pg/ml was an exclusion criteria, we were unable to
determine whether exposure to excessively elevated PTH
levels, as seen in severe hyperparathyroidism, would have a
deleterious effect on trabecular bone. The risk of osteoporosis
should not be underestimated in patients with secondary
hyperparathyroidism.
It is possible that cytokines involved in the regulation
of bone remodeling contributed to the bone loss observed
in our study. Recent studies using transgenic mice have
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Figure 1 | Osteoporosis distribution among renal osteodystrophy
types. ABD: adynamic bone disease; MUO: mixed uremic
osteodystrophy; PHBD: predominant hyperparathyroid bone
disease; and OM: osteomalacia.
Table 3 | Correlation coefficients between BV/TV and the
various clinical and biochemical parameters
Variable r P-value
TNFa 0.32 0.002
OPG/sRANKL ratio 0.29 0.005
Duration of amenorrhea 0.51 0.005
Age 0.27 0.006
OPG 0.24 0.02
BMI 0.18 0.07
sRANKL 0.19 0.08
BMI, body mass index; OPG, osteoprotegerin; sRANKL, soluble receptor-activator of
NF-kB ligand; TNFa, tumor necrosis factor.
Table 4 | Multiple stepwise linear regression analyses using
log BV/TV as a dependent variable
Variable b-Coefficient P-value 95% CI
Duration of amenorrhea 0.315 0.001 0.0013 to 0.0003
White race 0.255 0.008 0.148 to 0.231
OPG/sRANKL 0.215 0.026 0.001 to 0.0001
95% CI, 95% confidence interval; OPG, osteoprotegerin; sRANKL, soluble receptor-
activator of NF-kb ligand.
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demonstrated that the OPG/RANK/RANKL pathway plays a
role in regulating osteoclastogenesis.19–21 However, initial
studies involving uremic patients and evaluating the
influence of increased circulating levels of OPG22 in ROD
have produced conflicting results.23,24 In addition, it has been
suggested that determining the OPG/sRANKL ratio is a more
rational means of evaluating osteoclastogenesis than simply
determining OPG levels.25 In our study, OPG levels were
above the reference range in both the OP and the NOP group.
In the OP group, the OPG/sRANKL ratio was higher
(P¼ 0.04) and there was a trend toward higher OPG levels
(P¼ 0.06). Moreover, OPG levels and OPG/sRANKL ratio
correlated negatively with BV/TV. These conflicting results
could represent a homeostatic mechanism that limits the rate
of bone loss by decreasing bone resorption. Supporting this
hypothesis, a trend toward an inhibitory influence of OPG/
sRANKL ratio in bone resorption was noted, as evidenced by
the negative correlation between OPG/sRANKL ratio and the
eroded surface (P¼ 0.06). Yano et al.26 recently observed
similar correlations in postmenopausal OP women.
Interestingly, the results for TNFa were just the opposite
of those observed for OPG. In OP patients, TNFa levels were
lower (P¼ 0.006) and were positively correlated with BV/TV.
Previous studies have also suggested that TNFa acts like a
skeletal catabolic agent by stimulating bone resorption.27,28
Santos et al.29 found decreased expression of TNFa in bone
biopsy after parathyroidectomy in dialysis patients, suggest-
ing that this cytokine is involved in the regulation of bone
remodeling. Therefore, it seems reasonable to assume that
TNFa could also be involved in the homeostatic mechanism
of bone loss prevention. It is valid to question whether this
proposed mechanism represents an innocuous response. As
bone resorption precedes bone formation in the bone
remodeling cycle, increased OPG and decreased TNFa levels
would also lead to a delayed decrease in bone turnover. In
agreement with this hypothesis, we noted that BFR/BS
correlated negatively with OPG/sRANKL ratio (P¼ 0.05) and
positively with TNFa levels (P¼ 0.01). Studies providing a
better understanding of the bone microenvironment are
needed in order to elucidate this seeming paradox.
Regarding sex hormones, we were unable to demonstrate
any correlation of BV/TV with levels of estradiol or free
testosterone. In the case of our female patients, this could be
attributed to the small number of women included in this
study and to the fact that most of them were amenorrheic
(60%). However, three other findings suggested an effect of
female hypogonadism on trabecular bone volume in our
hemodialysis patients. First, amenorrheic women presented
significantly lower BV/TV than did menstruating women
(15.975.5% vs 22.979.6%; Po0.05; data not shown).
Second, longer duration of amenorrhea was negatively
correlated with BV/TV. Finally, patients who were ameno-
rrheic for more than 48 months were found to be at a 10-fold
greater risk for osteoporosis. Recent reports have addressed
the importance of sexual hormone status in the maintenance
of bone mass in hemodialyzed women.30,31 According to the
hormonal evaluation, only four of our male patients
presented hypogonadism. Owing to this small number of
hypogonadic men, the statistical analysis could not be
performed for this variable. In addition, there is clinical
evidence that the role of estrogens in the maintenance of
bone mass in males is more relevant than that of
testosterone.32
Finally, factors that were predictive of osteoporosis in our
study were similar to those found in dual-energy X-ray
absorptiometry evaluations of CKD patients and of the
general population.8,33–40 Such factors included advanced
age, being of the white race and, probably, low body mass
index. Although dual-energy X-ray absorptiometry is an
important diagnostic tool, it has limitations in the evaluation
of osteoporosis in CKD patients. Primarily, there is as yet no
agreement regarding which parameter (T-score or Z-score)
should be used to classify CKD patients as osteopenic or
OP.41 This fact may cause a misleading interpretation of the
data available. In addition, spinal osteophytes and aortic
calcification (both common findings in CKD patients) may
interfere with the accuracy of dual-energy X-ray absorptio-
metry in measuring bone mineral density in the lumbar
spine.42,43 Furthermore, bone mineral density correlates
poorly with bone remodeling and, consequently, with ROD
type.14,41 Nevertheless, other aspects must be considered
when evaluating osteoporosis through bone histomorpho-
metry. First, as suggested by Meunier et al.44, intersample
variation should be taken in account to assess the minimal
difference required in order to affirm that changes noted in a
repeat biopsy are significant. Second, although supposition
has yet to be proven, it has been suggested that another
histomorphometric parameter might be more sensitive or
specific than BV/TV in detecting bone loss.45 Therefore, there
is as yet no clear definition of osteoporosis based on bone
histomorphometry, especially in CKD patients. In an elegant
study involving OP patients with at least one vertebral
compression, Meunier et al.46 observed that BV/TV was
always less than 16%. The same author also defined the
‘vertebral fracture threshold’ as a BV/TV of approximately
11%.47 Kelepouris et al.48 observed that men aged 20 to 44
years with primary osteoporosis had a mean BV/TV of
18.675.4%, whereas OP men aged 45 to 60 years had a mean
BV/TV of 15.474.2%. In our study, patients had no history
of fracture. In addition, choosing a cutoff point below the
mean minus 1.0 s.d., it is supposed that only 16% of a given
population would fall below the normal range. This being so,
we can consider our cutoff point judicious for use in the
diagnosis of osteoporosis. However, more studies using bone
biopsy are required in order to clarify these aspects and to
investigate the links between bone mineral density, bone
histomorphometry, and clinical end points such as fracture
and vascular calcification.
In conclusion, to the best of our knowledge, this is the first
study that employed bone histomorphometry in order to
characterize osteoporosis in CKD patients. By considering
bone biopsy as the gold standard, osteoporosis was shown to
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be a truly prevalent bone disorder in hemodialysis patients.
In addition, we showed that even in the presence of normal
bone resorption, low bone formation could be involved in the
development of OP bone loss. Cytokines may also play a role
in this bone derangement, as may traditional risk factors such
as advanced age, hypogonadism, and white race.
MATERIALS AND METHODS
Patients
In this cross-sectional study, we evaluated 98 CKD patients on
standard hemodialysis treatment for 36.9724.7 months (range,
4–91 months). The sample consisted of 63 males and 35 females, and
the mean age was 48.4713.0 years. Of the 98 patients studied, 56
were white, eight were black, six were Asian, and 28 were of mixed
ethnicity. Body mass index was calculated for all patients. None of
the patients had a history of fracture. Data regarding smoking,
diabetes mellitus, and amenorrhea were recorded.
The present study makes reference to baseline data from an
ongoing randomized clinical trial comparing two phosphate
binders, sevelamer and calcium acetate, in hemodialysis patients.6
Therefore, based on the exclusion criteria for this study, the patients
presented no HIV infection, chronic inflammatory disease, current
use of corticosteroids, intact PTH levels 41000 pg/ml, or contin-
uous use of antiseizure drugs, nor were there any pregnant or
breastfeeding patients included.
The causes of renal failure were hypertension (27 patients),
chronic glomerulonephritis (17 patients), diabetic nephropathy
(nine patients), and other causes (18 patients). The etiology of the
renal failure was unknown in 27 patients. Of the 98 patients studied,
95 were currently taking calcium-containing phosphate binders
(either calcium acetate or calcium carbonate), and 52 had previously
taken calcitriol. Calcium concentration in the dialysate was
1.25 mmol/l for 18 patients and 1.75 mmol/l for 80 patients. Of
the 35 female patients, 21 were amenorrheic. None of the patients
had previously undergone parathyroidectomy or were undergoing
treatment with bisphosphonate or hormone replacement therapy.
The study was reviewed and approved by the ethics committee of
the local institution, and all patients gave written informed consent.
Biochemical parameters
Blood samples for the determination of biochemical parameters
were obtained before the first weekly hemodialysis session (after
patients had fasted overnight). In menstruating women, blood
sampling for measurement of sex hormones was performed during
the first week of the menstrual cycle (follicular phase).
Laboratory evaluation included ionized calcium (reference range:
1.11–1.40 mmol/l) and serum phosphorus (reference range:
2.3–4.5 mg/dl), determined by automated methods. Bone alkaline
phosphatase (reference range: 11.6–42.7 U/l) was measured by
enzyme immunoassay (Metra Biosystem Inc., Mountain View, CA,
USA). Serum deoxypyridinoline (reference range: 3.2570.66 nmol/
l) was determined by enzyme immunoassay (Quidel Corporation,
San Diego, CA, USA). Serum iPTH (reference range: 10–65 pg/ml)
was measured by chemiluminescence assay (DPC; Medlab, San
Antonio, TX, USA). Serum 25(OH) vitamin D (reference range:
18–62 ng/dl) was determined by radioimmunoassay (DiaSorin,
Stillwater, MN, USA). Serum OPG (reference range:
30.45712.1 pg/ml) and sRANKL (detection limit: 1.5 pg/ml) were
determined using a sandwich enzyme immunoassay (Immundiag-
nostik Laboratory, Bensheim, Germany). Serum TNFa (detection
limit: 2 pg/ml) was measured by enzyme immunoassay (Pharmin-
gen, San Diego, CA, USA). Serum estradiol (reference range:
1–30 ng/dl; menopause o3 ng/dl) and serum follicle-stimulating
hormone (reference: o12 U/l; menopause 430 U/l; and male
subjects o10 U/l) were measured by immunofluorometric assay.
Free testosterone (reference range: 9–55 pg/ml) was measured by
radioimmunoassay.
Bone biopsy
All patients were submitted to a transiliac bone biopsy using a
Bordier trephine, following a course of double-labeling tetracycline
(20 mg/kg/day) for 3 days, with a 10-day interval. The biopsy was
performed 3–5 days after the last dose of tetracycline and no longer
than 1 month after the blood sampling. Undecalcified bone
fragments were submitted to standard processing for histological
studies.49 Sections were stained with toluidine blue (pH¼ 6.4). Acid
solochrome azurine50 and Perls’ staining were employed to detect
deposits of aluminum and iron, respectively, in bone tissue.
Unstained sections were used for tetracycline fluorescence analysis.
Bone histomorphometry was conducted in a double-blind
protocol, using the semiautomatic method provided in the
Osteomeasure software (Osteometrics Inc., Atlanta, GA, USA).
The static and dynamic parameters were analyzed following the
standards established by the American Society of Bone and Mineral
Research.51 The reference ranges used for static parameters were
obtained from our normal laboratory controls, whereas the dynamic
followed those described elsewhere.52
On the basis of the histomorphometry, the patients were divided
into the following groups: (1) predominant hyperparathyroid bone
disease, defined as BFR/BS, as well as either osteoblast surface or
osteoclast surface, more than 1 s.d. above normal range, osteoid
volume within or above the normal range and marrow fibrosis
40.5%; (2) adynamic bone disease, defined as BFR/BS and osteoid
volume more than 1 s.d. below the normal range and marrow
fibrosis o0.5%; (3) osteomalacia, defined as BFR/BS more than
1 s.d. below the normal range and osteoid volume more than 1 s.d.
above the normal range; and (4) mixed uremic osteodystrophy,
defined as BFR/BS more than 1 s.d. below the normal range, osteoid
volume and osteoblast surface more than 1 s.d. above the normal
range and marrow fibrosis X0.5%. Aluminum-related bone disease
was defined as an aluminum bone surface greater than 25%.
In this study, osteoporosis was defined as BV/TV greater than
1 s.d. below normal range (M¼ 25.578.1%; F¼ 22.077.3%).
Therefore, osteoporosis was defined as a BV/TV lower than 14.7%
for female patients and lower than 17.4% for male patients.
Statistical analysis
Results are expressed as mean7s.d. or percentage. Either Student’s
t-test for unpaired data or non-parametric Mann–Whitney U-test
was used to elucidate differences between groups. Spearman’s
coefficient was used to describe correlations between BV/TV and
other variables. A multiple linear regression analysis adjusted for sex
and age was conducted in order to determine the relationship
between BV/TV and demographic, clinical, and biochemical
variable. All variables that reached statistical significance in the
univariate analysis were included in the model of the multiple
regression analysis. As BV/TV is not a normally distributed variable,
we used log BV/TV as the dependent variable in the regression
model. A P-value o0.05 was considered statistically significant. All
statistical analyses were carried out using the true Epistat program
(Epistat Services, Richardson, TX, USA).
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